Every 424B that Vivani Medical, Inc. (VANI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VANI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VANI filings page.
Vivani Medical, Inc. (VANI) registered for resale up to 3,947,368 shares of common stock issuable upon exercise of outstanding warrants held by Sabby Volatility Warrant Master Fund, Ltd. Vivani is not selling the shares and will receive no proceeds from holder resales, though it may receive proceeds upon warrant exercise.
The warrants have a $3.80 exercise price, subject to adjustment, were exercisable immediately upon issuance, and expire March 1, 2027. Cashless exercise is permitted if, at exercise, no effective registration statement registers the underlying shares or the prospectus is unavailable. Common shares outstanding were 90,203,356 as of August 13, 2026; the last reported sale price was $1.23 on September 24, 2026. Warrant exercises cannot result in ownership above 4.99%; holders may increase this limit to no greater than 9.99% after giving Vivani 61 days’ notice.
Vivani describes itself as a clinical-stage biopharmaceutical company developing subdermal drug implants using NanoPortal technology. Its lead program, NPM-139, is a six-month semaglutide implant in development for chronic weight management; other programs include NPM-133, NPM-115, and OKV-119, developed with animal health partner Okava Pharmaceuticals.
Vivani Medical, Inc. is conducting a registered direct offering of 1,689,200 shares of common stock at $1.48 per share, raising approximately $2.0 million in net proceeds. At the same time, an entity affiliated with director Gregg Williams has agreed to buy 1,351,351 additional shares in a concurrent private placement, expected to add about $1.9 million, for combined net proceeds of roughly $3.9 million. Vivani plans to use these funds, together with existing cash, to support research and clinical development of its long-acting drug implant programs, as well as working capital and general corporate purposes, and currently expects its cash resources to fund operations into mid 2027. Following the offering and the concurrent private placement, Vivani expects to have 81,206,080 shares of common stock outstanding, and notes that new buyers will experience dilution compared with earlier shareholders.
Vivani Medical, Inc. launched a registered direct offering of 6,000,000 shares of common stock at $1.62 per share. The company expects gross proceeds of $9,720,000, placement agent fees of 7.0%, and estimates net proceeds of approximately $8.7 million from this offering, with closing expected on or about October 28, 2025 subject to customary conditions.
Concurrently, an entity affiliated with director Gregg Williams agreed to purchase 3,703,703 shares in a separate private placement at the same price, generating an estimated additional $5.9 million in net proceeds; this sale is not part of the registered offering and carries no underwriting discounts or commissions. Combined net proceeds are approximately $14.7 million. Shares outstanding are expected to be 72,952,235 after the offering and concurrent private placement. Proceeds will fund research and clinical development, working capital, capital expenditures, and general corporate purposes, with management indicating funding into 2027.